JP2020507577A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507577A5
JP2020507577A5 JP2019543270A JP2019543270A JP2020507577A5 JP 2020507577 A5 JP2020507577 A5 JP 2020507577A5 JP 2019543270 A JP2019543270 A JP 2019543270A JP 2019543270 A JP2019543270 A JP 2019543270A JP 2020507577 A5 JP2020507577 A5 JP 2020507577A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
variable domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019543270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017718 external-priority patent/WO2018148610A1/en
Publication of JP2020507577A publication Critical patent/JP2020507577A/ja
Publication of JP2020507577A5 publication Critical patent/JP2020507577A5/ja
Priority to JP2022074378A priority Critical patent/JP2022105121A/ja
Withdrawn legal-status Critical Current

Links

JP2019543270A 2017-02-10 2018-02-10 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 Withdrawn JP2020507577A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022074378A JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457785P 2017-02-10 2017-02-10
US62/457,785 2017-02-10
PCT/US2018/017718 WO2018148610A1 (en) 2017-02-10 2018-02-10 Proteins binding psma, nkg2d and cd16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022074378A Division JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2020507577A JP2020507577A (ja) 2020-03-12
JP2020507577A5 true JP2020507577A5 (2) 2021-03-25

Family

ID=63107819

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543270A Withdrawn JP2020507577A (ja) 2017-02-10 2018-02-10 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
JP2022074378A Withdrawn JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022074378A Withdrawn JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Country Status (13)

Country Link
US (1) US20200024353A1 (2)
EP (1) EP3579878A4 (2)
JP (2) JP2020507577A (2)
KR (1) KR20190120770A (2)
CN (1) CN110913902A (2)
AU (1) AU2018217834A1 (2)
BR (1) BR112019016553A2 (2)
CA (1) CA3053275A1 (2)
IL (1) IL268574A (2)
MX (1) MX2019009541A (2)
RU (1) RU2019128204A (2)
SG (1) SG11201907271PA (2)
WO (1) WO2018148610A1 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
CN117881702A (zh) * 2021-08-03 2024-04-12 山东先声生物制药有限公司 一种cd16抗体及其应用
CN117915950A (zh) * 2021-08-06 2024-04-19 甘李药业股份有限公司 一种多特异性抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6455712B1 (en) * 2000-12-13 2002-09-24 Shell Oil Company Preparation of oxirane compounds
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
JP2009514537A (ja) * 2005-11-03 2009-04-09 ジェネンテック・インコーポレーテッド 治療的抗ｈｅｒ２抗体融合ポリペプチド
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
US8629247B2 (en) * 2009-04-14 2014-01-14 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
CN102947335B (zh) * 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
BR112014002716A2 (pt) * 2011-08-05 2017-06-13 Genentech Inc anticorpos anti-poliubiquitina e métodos de uso
HK1221908A1 (zh) * 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂，其制备方法和用途
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
MX2017006016A (es) * 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
JPWO2016111344A1 (ja) * 2015-01-08 2017-10-26 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2016134371A2 (en) * 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016135041A1 (en) * 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
RS61907B1 (sr) * 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
DK3313876T3 (da) * 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner

Similar Documents

Publication Publication Date Title
JP2020507577A5 (2)
JP2020510646A5 (2)
JP2020508997A5 (2)
JP2023052214A5 (2)
JP2020510653A5 (ja) Ｃｅａを標的にする多重特異性結合タンパク質
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
JP2023106433A5 (2)
JP2021098733A5 (2)
JP2020521448A5 (2)
JP2021534096A5 (2)
JP2021098732A5 (2)
JP2020507328A5 (2)
JP2020533311A5 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
RU2019128204A (ru) Белки, связывающиеся с psma, nkg2d и cd16
RU2019129511A (ru) Белки, связывающие gd2, nkg2d и cd16
JP2020522474A5 (2)
JP2021523140A5 (2)
JP2021533169A5 (2)
US11913025B2 (en) Antigen-specific T cells and uses thereof
JP2020529410A5 (2)
JP2020522473A5 (2)
JP2020536532A5 (2)
JP2023526774A5 (2)
FI3582806T3 (fi) Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
JP2017535257A5 (2)